<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study

    PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.

    Biodesix Closes Series D Financing - August 2012

    Biodesix has closed on a $12 million extension to its Series D financing. The new capital will support commercialization activities for VeriStrat.

    Peer-Reviewed Study Confirms VeriStrat® Test from Biodesix Provides Useful Information for Physicians in Managing Patients with Lung Cancer

    Study demonstrates that physicians are using the company’s VeriStrat test to help guide treatment decisions for patients with NSCLC.

    Biodesix Announces Results in Phase III Lung Cancer Diagnostic Study; First Prospective Biomarker-Stratified Validation Study in Oncology

    Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.

    VeriStrat® Test Predicts Differential Treatment Benefit between Chemotherapy and Targeted Therapy for Lung Cancer Patients

    Analysis showed that the VeriStrat test was able to identify patients more likely to have a slower progression of disease with select treatments.

    Biodesix’ Heinrich Roder Presents at 2013 Biomarker Summit

    Dr. Roder will discuss the use of Biodesix’ high throughput mass spectrometry technology, Deep MALDI, to generate protein signatures for Oncology questions.

    Biodesix to Present at World CDx

    Paul Beresford, Ph.D., will present at the 2013 World CDx Summit taking place in Boston, November 12-15, 2013; Benefits of proteomics in test discovery.

    Biodesix Secures Medicare Coverage for VeriStrat Test

    Bioesix's Veristrat test gains coverage from Medicare. More than 49 million Medicare enrollees in the U.S. will now be able to benefit from VeriStrat.

    Biodesix Closes Series E Financing

    Biodesix announced today that the company closed an $8.3 million Series E preferred equity financing. Existing shareholders provided all of the capital.

    Biodesix Adds to Series E Financing

    Biodesix increases the size of its recent offering of series E preferred shares in a follow-on sale; Total series E preferred shares of $14.4 million.